XELOX方案联合华蟾素胶囊治疗晚期结直肠癌的临床效果及安全性

Clinical effect and safety of XELOX regimen combined with Huachansu capsule in the treatment of advanced colorectal cancer

目的观察XELOX方案联合华蟾素胶囊治疗晚期结直肠癌(CRC)的临床效果及安全性。方法将62例晚期CRC患者随机分为对照组与治疗组,各31例。对照组单纯给予XELOX(卡培他滨+奥沙利铂)化疗方案,治疗组在对照组基础上给予华蟾素胶囊治疗。采用RECIST 1.1疗效评价系统比较两组临床疗效;比较两组治疗前、后CA199、CEA水平;按照CTCAE v 4.0对两组不良反应进行分级并评价;采用VAS评分比较两组患者疼痛缓解程度,采用KPS评分比较两组功能改善程度。结果治疗组ORR为67.74%,明显高于对照组的41.94%(P<0.05)。治疗后,两组血清CEA、CA199水平显著降低,且治疗组低于对照组(P<0.05)。治疗组Ⅰ~Ⅳ级胃肠道反应、骨髓抑制、肝功能损害、周围神经损害总发生率低于对照组(P<0.05)。治疗后,两组VAS评分明显降低,KPS评分明显升高,且治疗组优于对照组(P<0.05)。结论XELOX方案联合华蟾素胶囊治疗晚期CRC的临床效果明确,可降低毒副反应发生率,提升治疗的安全性,值得临床推广。

Objective To observe the clinical effect and safety of XELOX regimen combined with Huachansu capsule in the treatment of advanced colorectal cancer(CRC).Methods A total of 62 patients with advanced CRC were randomly divided into control group and treatment group,with 31 cases in each group.The control group was given XELOX(capecitabine+oxaliplatin)chemotherapy regimen alone,and the treatment group was treated with Huachansu capsule on the basis of the control group.RECIST 1.1 efficacy evaluation system was used to compare the clinical efficacy of the two groups;the CA199 and CEA levels before and after treatment were compared between the two groups;the adverse reactions of the two groups were graded and evaluated according to CTCAE v 4.0;the VAS score was used to compare the pain relief degree of the two groups,and the KPS score was used to compare the functional improvement degree of the two groups.Results The ORR of the treatment group was 67.74%,which was significantly higher than 41.94%of the control group(P<0.05).After treatment,the serum CEA and CA199 levels of the two groups significantly reduced,and those of the treatment group were lower than the control group(P<0.05).The total incidences of gradeⅠ-Ⅳgastrointestinal reaction,bone marrow suppression,liver function damage and peripheral nerve damage in the treatment group were lower than those in the control group(P<0.05).After treatment,the VAS score of the two groups decreased significantly,and the KPS score increased significantly,and those of the treatment group were better than the control group(P<0.05).Conclusion XELOX regimen combined with Huachansu capsule has a clear clinical effect in the treatment of advanced CRC,it can reduce the incidece of toxic and side effects,improve the safety of treatment,and which is worthy of clinical promotion.